PureTech Health plc
PRTC
Cena:
$ 17.25
0.00 (0.00%)
Valuace
100
Růst
30
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
PURETECH TO PRESENT AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
06-01-2026
BOSTON--(BUSINESS WIRE)--PURETECH TO PRESENT AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE....
Více zde
PURETECH APPOINTS ROBERT LYNE AS CHIEF EXECUTIVE OFFICER
18-12-2025
BOSTON--(BUSINESS WIRE)--PURETECH HEALTH PLC (NASDAQ: PRTC, LSE: PRTC) ("PURETECH" OR THE "COMPANY")...
Více zde
PURETECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA FOR DEUPIRFENIDONE (LYT-100) IN IDIOPATHIC PULMONARY FIBROSIS
08-12-2025
BOSTON--(BUSINESS WIRE)--PURETECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA FOR DEUPIRFEN...
Více zde
PURETECH'S FOUNDED ENTITY GALLOP ONCOLOGY ANNOUNCES POSITIVE INITIAL TOPLINE DATA FROM PHASE 1B TRIAL OF LYT-200 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME
05-12-2025
BOSTON--(BUSINESS WIRE)--PURETECH'S FOUNDED ENTITY GALLOP ONCOLOGY ANNOUNCES POSITIVE INITIAL TOPLIN...
Více zde
PURETECH PRESENTS NEW PHASE 2B ANALYSES DEMONSTRATING CONSISTENT SAFETY AND EFFICACY OF DEUPIRFENIDONE IN OLDER PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), A HISTORICALLY UNDERTREATED GROUP
22-10-2025
BOSTON--(BUSINESS WIRE)--PURETECH PRESENTS NEW PHASE 2B ANALYSES DEMONSTRATING CONSISTENT SAFETY AND...
Více zde
PURETECH PRESENTS NEW DATA FROM PHASE 2B OPEN-LABEL EXTENSION STUDY OF DEUPIRFENIDONE (LYT-100), FURTHER SUPPORTING STRONG AND DURABLE EFFICACY AND POTENTIAL TO SERVE AS NEW STANDARD OF CARE IN IPF
29-09-2025
BOSTON--(BUSINESS WIRE)--PURETECH PRESENTS NEW DATA FROM DEUPIRFENIDONE PHASE 2B OPEN-LABEL EXTENSIO...
Více zde
PURETECH HEALTH PLC – HALF-YEAR REPORT
28-08-2025
BOSTON--(BUSINESS WIRE)--PURETECH TODAY ANNOUNCES ITS HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED J...
Více zde
PURETECH SHOWCASES DIFFERENTIATED DEVELOPMENT STRATEGY, INCLUDING NEW PATIENT PREFERENCE INSIGHTS, AND SPOTLIGHTS PHASE 2B DATA POSITIONING DEUPIRFENIDONE AS A POTENTIAL NEW STANDARD OF CARE IN IPF
21-08-2025
BOSTON--(BUSINESS WIRE)--PURETECH DEMONSTRATES STRATEGIC AND SCIENTIFIC LEADERSHIP IN IDIOPATHIC PUL...
Více zde
PURETECH HEALTH: NOTICE OF HALF-YEARLY RESULTS
18-08-2025
BOSTON--(BUSINESS WIRE)--PURETECH HEALTH: NOTICE OF HALF-YEARLY RESULTS....
Více zde
PURETECH FOUNDED ENTITY VEDANTA BIOSCIENCES ANNOUNCES PHASE 2 STUDY OF VE202 IN ULCERATIVE COLITIS DID NOT MEET PRIMARY ENDPOINT
13-08-2025
BOSTON--(BUSINESS WIRE)--PURETECH FOUNDED ENTITY VEDANTA BIOSCIENCES ANNOUNCES PHASE 2 STUDY OF VE20...
Více zde
PURETECH ANNOUNCES THE LAUNCH OF CELEA THERAPEUTICS WITH A MISSION TO TRANSFORM THE TREATMENT OF RESPIRATORY DISEASES
12-08-2025
BOSTON--(BUSINESS WIRE)--PURETECH ANNOUNCES THE LAUNCH OF CELEA THERAPEUTICS WITH A MISSION TO TRANS...
Více zde
PURETECH ANNOUNCES LEADERSHIP TRANSITION
16-07-2025
BOSTON--(BUSINESS WIRE)--PURETECH ANNOUNCES LEADERSHIP TRANSITION....
Více zde
PURETECH ANNOUNCES BOARD CHANGE
08-07-2025
BOSTON--(BUSINESS WIRE)--PURETECH ANNOUNCES BOARD CHANGE....
Více zde
PURETECH HEALTH: RESULTS OF ANNUAL GENERAL MEETING
16-06-2025
BOSTON--(BUSINESS WIRE)--PURETECH HEALTH: RESULTS OF ANNUAL GENERAL MEETING....
Více zde
PURETECH TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE
22-05-2025
BOSTON--(BUSINESS WIRE)--PURETECH TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE....
Více zde
PURETECH ANNOUNCES PUBLICATION OF NEW RESEARCH HIGHLIGHTING UNTOLD EXPERIENCES OF PEOPLE LIVING WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
09-05-2025
BOSTON--(BUSINESS WIRE)--PURETECH ANNOUNCES PUBLICATION OF NEW RESEARCH HIGHLIGHTING UNTOLD EXPERIEN...
Více zde
PURETECH ANNOUNCES ANNUAL RESULTS FOR YEAR ENDED DECEMBER 31, 2024
30-04-2025
BOSTON--(BUSINESS WIRE)--PURETECH ANNOUNCES ANNUAL RESULTS FOR YEAR ENDED DECEMBER 31, 2024....
Více zde
PURETECH HEALTH: NOTICE OF RESULTS
23-04-2025
BOSTON--(BUSINESS WIRE)--PURETECH HEALTH: NOTICE OF RESULTS....
Více zde
PURETECH APPOINTS PEEL HUNT AS JOINT UK CORPORATE BROKER
09-04-2025
BOSTON--(BUSINESS WIRE)--PURETECH APPOINTS PEEL HUNT AS JOINT UK CORPORATE BROKER....
Více zde
PURETECH HEALTH PLC STATEMENT REGARDING PRESS SPECULATION
07-04-2025
BOSTON--(BUSINESS WIRE)--STATEMENT REGARDING PRESS SPECULATION....
Více zde
PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS ANNOUNCES THE PUBLICATION OF NEW RESEARCH DEMONSTRATING INCREASED LYMPHATIC TRANSPORT WITH UP TO 55 PERCENT DRUG ABSORPTION VIA LYMPHATICS WITH GLYPHTM PLATFORM
12-02-2025
BOSTON--(BUSINESS WIRE)--PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS ANNOUNCES PUBLICATION OF NEW R...
Více zde
PURETECH FOUNDED VEDANTA BIOSCIENCES PUBLISHES ADDITIONAL PHASE 2 VE303 RESULTS IN NATURE MEDICINE
27-01-2025
BOSTON--(BUSINESS WIRE)--PURETECH FOUNDED VEDANTA BIOSCIENCES PUBLISHES ADDITIONAL PHASE 2 VE303 RES...
Více zde
PURETECH RECEIVES FDA FAST TRACK DESIGNATION FOR LYT-200 IN ACUTE MYELOID LEUKEMIA (AML)
09-01-2025
BOSTON--(BUSINESS WIRE)--PURETECH RECEIVES FDA FAST TRACK DESIGNATION FOR LYT-200 IN ACUTE MYELOID L...
Více zde
PURETECH APPOINTS UBS AS UK CORPORATE BROKER
06-01-2025
BOSTON--(BUSINESS WIRE)--PURETECH APPOINTS UBS AS UK CORPORATE BROKER....
Více zde
PURETECH'S DEUPIRFENIDONE (LYT-100) SLOWED LUNG FUNCTION DECLINE IN PEOPLE WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AS MEASURED BY FORCED VITAL CAPACITY (FVC), ACHIEVING THE PRIMARY AND KEY SECONDARY ENDPOINTS IN THE ELEVATE IPF PHASE 2B TRIAL
16-12-2024
BOSTON--(BUSINESS WIRE)--PURETECH'S DEUPIRFENIDONE SLOWED LUNG FUNCTION DECLINE IN PEOPLE W/ IPF, AC...
Více zde
PURETECH PRESENTS DATA FOR LYT-200 (ANTI-GALECTIN-9 MONOCLONAL ANTIBODY) FOR RELAPSED/REFRACTORY AML/MDS AT THE 2024 ASH ANNUAL MEETING
09-12-2024
BOSTON--(BUSINESS WIRE)--PURETECH PRESENTS DATA FOR LYT-200 (ANTI-GALECTIN-9 MONOCLONAL ANTIBODY) FO...
Více zde
PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS ADDS SANDI PETERSON TO ITS BOARD OF DIRECTORS
20-11-2024
BOSTON--(BUSINESS WIRE)--PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS ADDS SANDI PETERSON TO ITS BOA...
Více zde
PURETECH HEALTH PLC – HALF-YEAR REPORT
28-08-2024
BOSTON--(BUSINESS WIRE)--PURETECH HEALTH PLC – HALF-YEAR REPORT....
Více zde
PURETECH HEALTH: NOTICE OF HALF-YEARLY RESULTS
21-08-2024
BOSTON--(BUSINESS WIRE)--PURETECH HEALTH: NOTICE OF HALF-YEARLY RESULTS....
Více zde
PURETECH HEALTH: RESULTS OF THE TENDER OFFER
24-06-2024
BOSTON--(BUSINESS WIRE)--PURETECH HEALTH: RESULTS OF THE TENDER OFFER....
Více zde
Dokumenty nejsou k dispozici
